Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
Selecta and Cyrus’ partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
President Joe Biden took an aggressive step that mandates vaccination for 100 million Americans who are eligible for preventative medication.
Acorda Therapeutics is reducing its staff count by 15% effective immediately as it struggles to bring operating costs down and hit expected revenue.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Los Altos, Calif.-based Evommune closed on a Series A financing round worth $83 million. The financing round included Andera Partners, LSP, Pivotal bioVenture Partners.
The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Norovirus vaccine is being developed at a rapid pace. HilleVax invests $135 million to rapidly progress the development. Here’s more about the vaccine.